Alkermes (ALKS) vs HUTCHMED (China) (HCM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alkermes (ALKS) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 29.4% versus a loss of 12.0%. Over five years, ALKS leads with a +28.2% price change compared with -56.3% for HCM. Alkermes is the larger company by market cap ($6.81 billion vs $2.45 billion), about 2.8 times the size.
On valuation, Alkermes trades at a lower forward P/E (22.5x vs 54.4x for HUTCHMED (China)). HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus 16.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | HCM |
|---|---|---|
| Share price | $40.61 | $14.10 |
| Market cap | $6.81B | $2.45B |
| 1-day change | +1.25% | +3.15% |
| YTD return | +45.14% | +5.78% |
| 1-year return | +29.41% | -11.99% |
| 5-year return | +28.23% | -56.35% |
| P/E ratio (TTM) | 106.87 | 141.00 |
| Forward P/E | 22.46 | 54.40 |
| EPS (TTM) | $0.38 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | $548.51M |
| Revenue growth (YoY) | -5.25% | -12.96% |
| Net income (latest FY) | $241.66M | $456.91M |
| Gross margin | 86.69% | 38.68% |
| Operating margin | 17.21% | -7.14% |
| Net margin | 16.37% | 83.30% |
| 52-week high | $55.67 | $16.33 |
| 52-week low | $27.00 | $9.77 |
| Distance from 52-week high | -27.05% | -13.66% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +38.59% | +56.10% |
| Average volume | 1.86M | 68.22K |
| Shares outstanding | 167.76M | 173.81M |
| Employees | 2,050 | 1,790 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alkermes is about 2.8 times larger than HUTCHMED (China) by market value ($6.81B vs $2.45B).
- ALKS has outperformed HCM by 41.4 percentage points over the past year.
- HUTCHMED (China) trades at a higher earnings multiple (141.0x vs 106.9x trailing P/E).
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus 16.4 cents for Alkermes.
- Alkermes grew revenue faster in its latest fiscal year (-5.25% vs -12.96%).
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
ALKS vs HCM FAQ
Which is bigger, Alkermes or HUTCHMED (China)?
Alkermes (ALKS) is larger, with a market capitalization of $6.81B compared with $2.45B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, ALKS or HCM?
ALKS returned +29.41% over the past 12 months, compared with -11.99% for HCM (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALKS or HCM?
ALKS has the lower trailing P/E at 106.9, versus 141.0 for HCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alkermes and HUTCHMED (China) in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.